Bod Australia (ASX:BDA) - CEO, Jo Patterson
CEO, Jo Patterson
Source: InvestorStream
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medicinal cannabis company Bod Australia (BDA) has received firm commitments to undertake an $8 million placement
  • Roughly 14.5 million new fully-paid ordinary shares will be issued to institutional and sophisticated investors at 55 cents each
  • Bod will use the money to launch new products, progress revenue generating activities, and promote growth in Australia
  • Bod has ended the day 2.44 per cent in the red with shares trading at 60 cents

Bod Australia (BDA) has received firm commitments to undertake an $8 million placement.

The medicinal cannabis company entered a trading halt only yesterday but did reveal how much it would be raising or what the funds would go towards.

Roughly 14.5 million new fully-paid ordinary shares will be issued to institutional and sophisticated investors at 55 cents each.

Bod will use the money to launch new products, progress revenue generating activities, and promote growth in Australia.

“We are particularly pleased with the level of support from existing institutional shareholders, affirming shareholder support and further validating the company’s international expansion strategy for its portfolio of CBD and hemp based products,” CEO Jo Patterson commented.

‘The funds raised will provide us with considerable financial flexibility and enable us to accelerate the launch of new products and to expand our presence in a number of key international markets including the European Union and North America,” she said.

“We have a number of near term, revenue-generating opportunities in these markets and we look forward to updating shareholders on developments in the coming months,” she added.

Bod has ended the day 2.44 per cent in the red with shares trading at 60 cents in a $56.19 million market cap.

BDA by the numbers
More From The Market Online
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…
Immune system concept ai gen

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has…